Support Local News.

At a moment of historic disruption and change with the ongoing COVID-19 pandemic, and the calls for social and racial justice, there's never been more of a need for the kind of local, independent and unbiased journalism that The Day produces.
Please support our work by subscribing today.

Plea deal doesn't match Purdue Pharma's opioid crime

This editorial appeared in the Los Angeles Times.

The prescription opioid crisis that has taken well over 100,000 American lives and ruined hundreds of thousands more wasn't just an accident of time or the byproduct of a dysfunctional society. It was in good part the deliberate result of unethical and occasionally illegal machinations by the pharmaceutical industry, particularly by Purdue Pharma, which paid kickbacks and willfully misled physicians and the public to boost sales of its addictive signature drug, OxyContin.

The company has now agreed to plead guilty to criminal charges in a federal settlement that doesn't even begin to make up for the harm Purdue has caused. It takes back hardly any of the billions the company has made while addicting a nation. Despite Purdue's admission of guilt and a settlement purportedly worth $8.3 billion, the agreement is a whole lot less than it seems.

The actual payout is expected to be a fraction of that size. The U.S. Justice Department agreed not to seek more than $225 million of the $2 billion criminal forfeiture called for in the deal if the company reorganizes as a public benefit entity overseen by state and local government. The government will probably get pennies on the dollar for the rest of the settlement, as the company is in bankruptcy court and the list of creditors is long.

Meanwhile, the Sackler family, which owns Purdue, is contributing $225 million of its fortune to the current agreement. The family says the public-benefit company would eventually pay $10 billion to settle the many other lawsuits it faces from state and local governments, but only over time, from future sales of OxyContin and an antidote drug, along with the proceeds from the sale of another Sackler-owned company.

This isn't the justice that a nation battered by opioid addiction needed.

Purdue reaped an estimated $30 billion in sales from OxyContin, and the Sacklers withdrew more than $10 billion from the company's assets over the past decade, according to an audit performed as part of bankruptcy proceedings. The public has a right to know whether the family is escaping a realistic accounting of what it holds and what it owes, both to victims and to the state and local governments that have borne the heavy cost of curbing the crisis.

The federal agreement does not exclude the possibility of criminal charges against members of the family or executives and employees of the company; the Justice Department says it is investigating the possibility, and it must. The evidence compiled so far, in internal emails and other documents, is dismaying.

There is a lot to answer for here. The current agreement, however, doesn't begin to make the needed restitution for the human and economic toll Purdue Pharma inflicted on this country.


The Day editorial board meets regularly with political, business and community leaders and convenes weekly to formulate editorial viewpoints. It is composed of President and Publisher Tim Dwyer, Editorial Page Editor Paul Choiniere, Managing Editor Tim Cotter, Staff Writer Julia Bergman and retired deputy managing editor Lisa McGinley. However, only the publisher and editorial page editor are responsible for developing the editorial opinions. The board operates independently from the Day newsroom.


Loading comments...
Hide Comments